Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study

BJU International

Volumn 105, Issue 7, 2010, Pages 956-962

  Van Den Bergh, Roderick C N ^a   Vasarainen, Hanna ^b   Van Der Poel, Henk G ^c   Vis Maters, Jenneke J ^d   Rietbergen, John B ^e   Pickles, Tom ^f   Cornel, Erik B ^g   Valdagni, Riccardo ^h   Jaspars, Joris J ⁱ   Van Der Hoeven, John ^j   Staerman, Frederic ^k   Oomens, Eric H G M ^l   Rannikko, Antti ^b   Roemeling, Stijn ^a   Steyerberg, Ewout W ^a   Roobol, Monique J ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^e SINT FRANCISCUS GASTHUIS   (Netherlands)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Hospital Group Twente   (Netherlands)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ Oosterschelde Hospital   (Netherlands)

^j REINIER DE GRAAF HOSPITAL   (Netherlands)

^k REIMS UNIVERSITY HOSPITAL   (France)

^l AMPHIA HOSPITAL   (Netherlands)

more..

Author keywords

Active surveillance; Biopsy; Outcomes; Prostate cancer; PSA; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; BIOPSY, NEEDLE; CANADA; EPIDEMIOLOGIC METHODS; EUROPE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77749286517     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08887.x     Document Type: Article

References (31)

1. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360 : 1320 1328
2. Roemeling S, Roobol MJ, de Vries SH et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007 51 : 1244 1250
3. van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009 55 : 1 8
4. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008 358 : 1250 1261
5. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004 5 : 101 106 (Pubitemid 38145893)
6. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002 167 : 1664 1669
7. Hardie C, Parker C, Norman A et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005 95 : 956 960 (Pubitemid 40655686)
8. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002 167 : 1231 1234
9. Dall'Era MA, Konety BR, Cowan JE et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008 112 : 2664 2670
10. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol 2008 180 : 1336 1339
11. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008 101 : 165 169
12. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: The PRIAS study. Eur Urol 2007 52 : 1560 1563
13. Schroder FH Denis LJ, Roobol M et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003 92 (Suppl. 2 1 13
14. Prostate Cancer research International. Active Surveillance. Available at: http://www.prias-project.org. Accessed March 2009
15. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland. J Urol 1998 159 : 920 924
16. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360 : 1320 8
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 2101 (Pubitemid 40617061)
18. Latini DM, Hart SL, Knight SJ et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007 178 : 826 831
19. van den Bergh RC, Essink-Bot ML, Roobol MJ et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009 115 : 3868 3878
20. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int 2007 100 : 544 551
21. Choo R, Danjoux C, Morton G et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007 67 : 1614 1620
22. Al Otaibi M, Ross P, Fahmy N et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008 113 : 286 92
23. Capitanio U, Karakiewicz PI, Valiquette L et al. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009 73 : 1087 1091
24. Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008 113 : 2068 2072
25. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009 181 : 1628 1633
26. van den Bergh RC, Steyenberg EW, Khatami A et al. Is delayed radical prostatectomy in men with early screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2009 (in press)
27. Klotz L. A phase III study of active surveillance therapy againts radical treatment in patients diagnosed with favourable risk prostate cancer (START) 2008. Available at: http://www.ctg.queensu.ca/trials/genito-urinary/pr11/pr11. html. Accessed March 2009
28. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008 100 : 1144 1154
29. Gao X, Mohideen N, Flanigan RC, Waters WB, Wojcik EM, Leman CR. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. J Urol 2000 164 : 1982 1986
30. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007 177 : 107 112
31. Eggener SE, Mueller A, Berglund RK et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009 181 : 1635 1641